OncoMatch/Clinical Trials/NCT07432633

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Is NCT07432633 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies [18F]FPyQCP for colorectal cancer.

Phase 1/2RecruitingBlue Earth DiagnosticsNCT07432633Data as of May 2026

Treatment: [18F]FPyQCP — This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Ovarian Cancer

Gastric Cancer

Breast Carcinoma

Pancreatic Cancer

Disease stage

Required: Stage I, II, III

Excluded: Stage IV (EXCEPT OLIGOMETASTATIC DISEASE [5 OR FEWER KNOWN METASTASES])

stage I-III (see Appendix 3) CRC, GC, PDAC, ILC, or EOC (stage IV disease is allowed in the setting of oligometastatic disease [5 or fewer known metastases])

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Texas Southwestern Medical Center · Dallas, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify